Endostatin and anastellin inhibit distinct aspects of the angiogenic process

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Neskey, David M ^a   Ambesi, Anthony ^a   Pumiglia, Kevin M ^a   McKeown Longo, Paula J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTELLIN; ANGIOGENESIS INHIBITOR; ENDOSTATIN; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; FIBRONECTIN; PEPTIDE FRAGMENT;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STIMULUS RESPONSE; ENDOTHELIUM CELL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; ENDOSTATINS; ENDOTHELIAL CELLS; FIBRONECTINS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS;

EID: 56349130649     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-61     Document Type: Article

References (51)

1. Tumor angiogenesis. RS Kerbel, New Eng J Med 2008 358 2039 2049 10.1056/NEJMra0706596 18463380
2. Tumor microenvironment and angiogenesis. P Nyberg T Salo R Kalluri, Frontiers in Biosci 2008 13 6537 6553 10.2741/3173
3. Endogenous inhibitors of angiogenesis. P Nyberg L Xie R Kalluri, Cancer Res 2008 65 3967 3979 10.1158/0008-5472.CAN-04-2427
4. Secreted cathespin L generates endostatin from collagen XVIII. U Felbor L Dreier RA Bryant HL Ploegh BR Olsen R Timple, EMBO J 2000 19 1187 1194 10716919 10.1093/emboj/19.6.1187
5. Antiangiogenesis in cancer therapy-endostatin and its mechainsms of action. J Folkman, Exp Cell Res 2006 312 594 607 10.1016/j.yexcr.2005.11.015 16376330
6. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. MS O'Reilly T Boehm Y Shing N Fukai G Vasios WS Lane, Cell 1997 88 277 285 10.1016/S0092-8674(00)81848-6 9008168
7. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Hanai M Dhanabal SA Karumanchi C Albanese M Waterman B Chan, J Biol Chem 2002 277 19 16464 16469 10.1074/jbc.M112274200 11815623
8. Caspases: Intracellular signaling by proteolysis. GS Salvesen VM Dixit, Cell 1997 91 443 446 10.1016/S0092-8674(00)80430-4 9390553
9. The biology of the small leucine-rich proteoglycans. RV Iozzo, J Biol Chem 1999 274 18843 18846 10.1074/jbc.274.27.18843 10383378
10. Endostatin's antiangiogenic signaling network. A Abdollahi P Hahnfeldt C Maercker HJ Grone J Debus W Ansorge, Mol Cell 2004 13 649 663 10.1016/S1097-2765(04)00102-9 15023336
11. Interaction of endostatin with integrins implicated in angiogenesis. M Rehn T Veikkola E Kukk-Valdre H Nakamura M Ilmonen C Lombardo, Proc Natl Acad Sci USA 2001 98 1024 1029 11158588 10.1073/pnas.031564998
12. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. A Sudhakar H Sugiomoto C Yang J Lively M Zeisberg R Kalluri, Proc Natl Acad Sci USA 2003 100 4766 4771 12682293 10.1073/pnas.0730882100
13. E-selectin is required for the antiangiogenic activity of endostatin. Y Yu KS Moulton MK Kahn S Vineberg E Boye VM Davis, Proc Natl Acad Sci USA 2004 101 8005 8010 15148373 10.1073/pnas.0402551101
14. Cell surface glypicans are low-affinity endostatin receptors. SA Karumanchi V Jha R Ramchandran A Karihaloo L Tsiokas B Chan, Mol Cell 2001 7 811 822 10.1016/S1097-2765(01)00225-8 11336704
15. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. SA Wickstrom K Alitalo J Keski-Oja, J Biol Chem 2003 278 37895 37901 10.1074/jbc.M303569200 12851410
16. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. R Pasqualini S Bourdoulous E Looivunen VL Woods Jr E Ruoslahti, Nat Med 1996 2 1197 1203 10.1038/nm1196-1197 8898745
17. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. M Yi E Ruoslahti, Proc Natl Acad Sci 2001 98 620 624 11209058 10.1073/pnas.98.2.620
18. Anastellin, a fragment of the first type III repeat of fibronectin, inhibits extracellular signal-regulated kinase and causes G1 arrest in human microvessel endothelial cells. A Ambesi RM Klein KM Pumiglia PJ McKeown-Longo, Cancer Res 2005 65 148 156 15665290
19. Cell adhesion and signaling on the fibronectin 1st type III repeat; requisite roles for cell surface proteoglycans and integrins. K Mercurius A Morla, BMC Cell Biol 2001 2 18 30 11591215 10.1186/1471-2121-2-18
20. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. S Bourdoulous G Orend DA MacKenna R Pasqualini E Ruoslahti, J Cell Biol 1998 143 267 276 9763437 10.1083/jcb.143.1.267
21. Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin. RM Klein M Zheng A Ambesi L van de Water PJ McKeown-Longo, J Cell Sci 2003 116 4663 4674 10.1242/jcs.00778 14576359
22. Endostatin reduces vascularization, blood flow, and growth in rat gliosarcoma. DR Sorensen TA Read T Porwol BR Olsen R Timpl T Sasaki, Neuro Oncol 2002 4 1 8 11772427 10.1215/15228517-4-1-1
23. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. DK Skovseth MJ Veuger DR Sorensen PM De Angelis G Haraldsen, Blood 2005 105 1044 1051 10.1182/blood-2004-03-1164 15466935
24. Endogenous endostatin inhibits choroidal neovascularization. AG Marneros H She H Zambarakji H Hashizume EJ Connolly I Kim, FASEB J 2007 21 3809 3818 10.1096/fj.07-8422com 17526870
25. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. K Eriksson P Magnusson J Dixelius L Claesson-Welch M Cross, FEBS Letters 2003 536 19 24 10.1016/S0014-5793(03)00003-6 12586331
26. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. S Ergun N Kilic JH Wurmbach A Ebrahimnejad M Fernando S Sevinc, Angiogenesis 2001 4 193 206 10.1023/A:1014027218980 11911017
27. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. T Boehm J Folkman T Browder MS O'Reilly, Nature 1997 390 404 407 10.1038/37126 9389480
28. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. Y-M Kim S Hwang Y-M Kim B-J Pyun T-Y Kim S-T Lee, J Biol Chem 2002 277 27872 27879 10.1074/jbc.M202771200 12029087
29. p38 MAP kinase - a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. K Issbrucker HH Marti S Hippenstiel R Vowinckel A Gaumann G Breier, FASEB J 2003 17 262 264 12490545
30. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. MS O'Reilly L Holmgren Y Shing C Chen RA Rosenthal M Moses, Cell 1994 79 315 328 10.1016/0092-8674(94)90200-3 7525077
31. 1arrest of endothelial cells through inhibition of cyclin D1. J Hanai M Dhanabal SA Karumanchi C Albanese M Waterman B Chang, J Biol Chem 2002 277 16564 16469 10.1074/jbc.M112274200
32. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. R Heljasvaara P Nyberg J Luostarinen M Parikka P Heikkila M Rehn, Exp Cell Res 2005 307 292 304 10.1016/j.yexcr.2005.03.021 15950618
33. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. RC Reis D Schuppan AC Barreto M Bauer JP Bork G Hassler, Biochem Biophys Res Commun 2005 333 976 983 10.1016/j.bbrc.2005.06.011 15985216
34. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. X Zhang J Hu J Lawler E Terwillliger S Parangi, Clin Cancer Res 2007 13 3968 3976 10.1158/1078-0432.CCR- 07-0245 17606731
35. Opposite effects of endostatin on different endothelial cells. A Schmidt K Addicks W Bloch, Cancer Biol Ther 2004 3 1162 1166 15640622
36. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. A Abdollahi KE Lipson A Sckell H Zieher F Klenke D Poerschke, Cancer Res 2003 63 8890 8898 14695206
37. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. SA Wickstrom K Alitalo J Keski-Oja, J Biol Chem 2004 279 20178 20185 10.1074/jbc.M312921200 14973128
38. Regulation of p38 MAP kinase by anastellin is independent of anastellin's effect on matrix fibronectin. R You RM Klein M Zheng PJ McKeown-Longo, Matrix Biol 2008
39. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Y Maeshima A Sudhakar JC Lively K Ueki S Kharbanda CR Kahn, Science 2002 295 140 143 10.1126/science.1065298 11778052
40. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. DJ Panka JW Mier, J Biol Chem 2003 278 37632 37636 10.1074/jbc.M307339200 12876280
41. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. GD Kamphaus PC Colorado DJ Panka H Hopfer R Ramchandran A Torre, J Biol Chem 2000 275 1209 1215 10.1074/jbc.275.2.1209 10625665
42. Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. A Sudhakar P Nyberg VG Keshamouni AP Mannam J Li H Sugimoto, J Clin Invest 2005 115 2801 2810 16151532 10.1172/JCI24813
43. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. JR Ohlfest ZL Demorest Y Motooka I Vengco S Oh E Chen, Mol Ther 2005 12 778 788 10.1016/j.ymthe.2005.07.689 16150649
44. Mechanism of formation of disulfide-bonded multimers of plasma fibronectin in cell layers of cultured human fibroblasts. PJ McKeown-Longo DF Mosher, J Biol Chem 1984 259 12210 12215 6480605
45. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Q Zhang M Nie J Sham C Su H Xue D Chua, Cancer Res 2004 64 5390 5397 10.1158/0008-5472.CAN-04- 1229 15289347
46. Intraperitoneal gene therapy by rAAV provides long-term survival epithelial ovarian cancer independently of survivin pathway. T Isayeva C Ren S Ponnazhagan, Gene Ther 2007 14 138 146 16943851
47. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. X Li YH Liu SJ Lee TA Gardner MH Jeng C Kao, Clin Cancer Res 2008 14 291 299 10.1158/1078-0432.CCR-07-0867 18172281
48. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice. J Li X Dong Z Xu X Jiang H Jiang GW Krissansen, J Biomed Sci 2008 15 99 109 10.1007/s11373-007-9201-3 17705027
49. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. B Yao QM He L Tian F Xiao Y Jiang R Xhang, Human Gene Therapy 2005 9 1075 1086 10.1089/hum.2005.16.1075
50. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. G Brideau JJ Makinen H Elamaa H Tu G Nilsson K Alitalo, Cancer Res 2007 67 11528 11535 10.1158/0008-5472.CAN-07-1458 18089781
51. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. T Isayeva D Chanda L Kallman IE Eltoum S Ponnazhagan, Cancer Res 2007 67 5789 5797 10.1158/0008-5472.CAN-06-3637 17575146